When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
Though there are channels through which terminally ill patients can access some experimental drugs that have not yet received FDA approval for marketing to the public, in general those drugs must already be proven safe and effective.
Rachel O. Reid, MD, MS and Ateev Mehrotra, MD, MPH
An effective policy regarding retail clinics in a primary care practice should address patients' need for timely and convenient acute care and build capacity for enhanced access to acute care within the primary care clinic itself.
CBP researchers are challenged to think strategically about ways to convey their accomplishments and educate their non-CBPR peers about the nature of their research, processes not required of traditional researchers.
Elizabeth Lee Daugherty, MD, MPH and Douglas B. White, MD, MA
Opportunities to advance scientific knowledge may arise during humanitarian crises, but their presence does not justify suspension of the ethical foundations governing human subjects research.
Krishna Lynch, RN, MJ, CPHRM and Rita F. Morris, RN, MJ
Court decisions on nurse liability draw a fine line between failing to take action in the patient’s best interest and advocating for patients in an uncollaborative manner.